On 18 March, Eisai presented four-year data from its OLE period of its Phase III CLARITY-AD trial of Leqembi to treat early ...
The appeals panel upheld a portion of appeals raised by Eisai and Eli Lilly over the process NICE used to recommend against ...
BioArctic's AB (publ) (NASDAQ: BIOA B) partner Eisai presented new data at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™), held ...
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term Treatment TOKYO and CAMBRIDGE, Mass., Mar 23, 2026 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that new ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. announced today that new real?world findings ...
Real-World LEQEMBI Data Shows Patients Choose to Stay on Long-Term TreatmentTOKYO and CAMBRIDGE, Mass., March 20, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ...
NHS watchdogs will re-evaluate their decision not to fund two new Alzheimer’s treatments on the health service after appeals ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
A new drug, FLAV-27, targets epigenetic changes in Alzheimer’s. In preclinical studies, the drug reduced levels of ...
Morning Overview on MSN
New “intrabodies” could lead to treatments for MND and Alzheimer’s
Researchers are engineering a new class of miniature antibodies, called intrabodies, that can operate inside living cells to ...
The U.K.’s national health spending watchdog will reevaluate its decision to exclude the use of two Alzheimer’s drugs ...
After a successful appeal, reimbursement authority NICE has said the companies' files will now be sent back to the appraisal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results